DSGN vs AVBP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DSGN · Design Therapeutics$10.21 ▲ 5.58%
AVBP · ArriVent BioPharma$13.64 ▲ 11.53%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DSGN +37.4%
- AVBP -26.7%
Head to head
| Metric | DSGN | AVBP |
|---|---|---|
| Price | $10.21 | $13.64 |
| Change today | ▲ 5.58% | ▲ 11.53% |
| Market cap | $653.81M | $672.56M |
| Return, 3 months | -28.8% | -56.0% |
| Return, year to date | +8.8% | -32.2% |
| Return, 1 year | +35.1% | -24.4% |
| P/E (TTM) | – | – |
| P/B | 3.2 | 1.8 |
| P/E percentile vs own 5y | 33rd | 100th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -5.7% | -58.9% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -34.1% | -53.1% |
| Analyst target vs. price | +122.0% | +130.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 42 | 35 |
| 30-day volatility | 65.6% | 220.3% |
| Max drawdown, 1 year | -39.3% | -64.8% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AVBP is the largest of the group by market value.
- DSGN has returned the most over the past year.
- DSGN has been the calmest stock over the last 30 days.